Ribonucleoside Diphosphate Reductase
"Ribonucleoside Diphosphate Reductase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the formation of 2'-deoxyribonucleotides from the corresponding ribonucleotides using NADPH as the ultimate electron donor. The deoxyribonucleoside diphosphates are used in DNA synthesis. (From Dorland, 27th ed) EC 1.17.4.1.
Below are MeSH descriptors whose meaning is more general than "Ribonucleoside Diphosphate Reductase".
Below are MeSH descriptors whose meaning is more specific than "Ribonucleoside Diphosphate Reductase".
This graph shows the total number of publications written about "Ribonucleoside Diphosphate Reductase" by people in Harvard Catalyst Profiles by year, and whether "Ribonucleoside Diphosphate Reductase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
Below are the most recent publications written about "Ribonucleoside Diphosphate Reductase" by people in Profiles.
-
RRM1 variants cause a mitochondrial DNA maintenance disorder via impaired de novo nucleotide synthesis. J Clin Invest. 2022 07 01; 132(13).
-
Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma. Anticancer Res. 2021 Oct; 41(10):4821-4836.
-
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mol Oncol. 2020 08; 14(8):1881-1897.
-
Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer. Mol Oncol. 2019 09; 13(9):1944-1958.
-
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
-
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem. 2018 01 19; 293(3):984-994.
-
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
-
Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. Mol Cell. 2015 Sep 17; 59(6):1011-24.
-
A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development. Mol Cell Biol. 2015 Sep 01; 35(17):2910-7.
-
Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes Dev. 2015 Apr 01; 29(7):690-5.